MAP2K1 and oral cavity cancer: Here, we utilize newly described syngeneic MOC models of murine oral cavity cancer [20] to demonstrate differential effects of the mTOR inhibitor rapamycin and the MEK1/2 inhibitor PD901 alone or in combination on oncogenic signaling, tumor responses and survival and immune modulation in highly immunogenic (MOC1) and poorly immunogenic (MOC2) tumors.